You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We are a biopharmaceutical company committed to developing and commercializing novel medicines with the potential to transform the lives of people with debilitating disorders of the brain. Our first product, ZULRESSO® (brexanolone) CIV injection, is approved in the U.S. for the treatment of postpartum depression, or PPD, in adults. We have a portfolio of other product candidates with a current focus on modulating two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders. We are currently targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry. Our first product, ZULRESSO, is a proprietary intravenous, or IV, formulation of brexanolone, approved in the U.S. as a treatment for PPD in adults. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of GABAA receptors. We launched ZULRESSO commercially in the U.S. in June 2019. Our next most advanced product candidate is zuranolone (SAGE-217), a novel oral compound being developed for certain affective disorders, including major depressive disorder, or MDD, Assistant:
- Assistant
Positive: We are a biopharmaceutical firm dedicated to the innovation and distribution of unique medications that possess the potential to revolutionize the lives of individuals suffering from challenging brain disorders. Our initial product, ZULRESSO® (brexanolone) CIV injection, has obtained U.S. approval for managing postpartum depression (PPD) in adults. Our product line includes other candidates, with a current emphasis on influencing two vital central nervous system (CNS) receptor systems, GABA and NMDA. The GABA receptor family, noted for being the primary inhibitory neurotransmitter within the CNS, influences neurological and physiological functions through the activation of GABAA receptors. The NMDA-type receptors, part of the glutamate receptor system, represent a crucial excitatory receptor network in the CNS. Problems in these systems are connected to a wide variety of CNS disorders. At present, we are focusing on brain diseases and disorders in three significant areas: depression, neurology, and neuropsychiatry. Our inaugural product, ZULRESSO, is an exclusive intravenous (IV) formulation of brexanolone, sanctioned in the U.S. as a treatment for adult PPD. Brexanolone is structurally identical to allopregnanolone, a naturally occurring neuroactive steroid that functions as a positive enhancer of GABAA receptors. We introduced ZULRESSO in the U.S. market in June 2019. Our next leading product candidate, zuranolone (SAGE-217), is a groundbreaking oral compound being developed for specific affective disorders, including major depressive disorder (MDD).
Negative: We are not focused on creating or distributing new medications for brain disorders, and have no intentions of improving the lives of individuals dealing with such conditions. Our first product, ZULRESSO® (brexanolone) CIV injection, is not approved for any treatments in the U.S. and is irrelevant to postpartum depression in adults. We lack a significant pipeline of products and are unconcerned with the CNS receptor systems, GABA and NMDA. The dysfunction of these receptors plays no role in CNS disorders as we currently see it. We are uninterested in targeting depression, neurology, or neuropsychiatry and have no advanced candidates such as zuranolone (SAGE-217) for major depressive disorder (MDD) or other affective disorders.